HRH the Crown Prince and Prime Minister visits the world’s first sickle cell disease patient outside of the United States to successfully complete treatment with Casgevy

The Bone Marrow and Stem Cell Transplant Unit at the Royal Medical Services, Bahrain Oncology Center, has treated the world’s first sickle cell disease patient outside the United States with Casgevy (exagamglogene autotemcel), a CRISPR-based gene-editing therapy combined with bone marrow transplantation.

 

His Royal Highness Prince Salman bin Hamad Al Khalifa, the Crown Prince and Prime Minister, visited the hospital to congratulate the patients and check their well-being. He emphasized Bahrain’s commitment to staying at the forefront of medical advancements to better serve the Bahraini people. This success underscores Bahrain’s dedication to world-class healthcare.

 

In line with His Majesty the King’s vision and under the direction of HRH the Crown Prince and Prime Minister, the National Health Regulatory Authority has approved “CASGEVY (Exa-cel)” for patients with sickle cell anemia (sickle cell) and beta-thalassemia, after a thorough review of clinical trials. Bahrain is the first country in the region and the second globally to approve this treatment, further solidifying its leadership in healthcare innovation.

 

Read more here